Detailed introduction to the usage and dosage of selumetinib/coceyu

Selumetinib is a selective MEK1/2 inhibitor approved by the FDA for the treatment of pediatric patients with neurofibromatosis type 1 (NF1), particularly those with symptomatic and inoperable plexiform neurofibromas (PN). This drug inhibits the growth and division of tumor cells by blocking the RAS/RAF/MEK/ERK signaling pathway, thereby achieving the purpose of controlling tumor progression. Since NF1 is a hereditary disease, traditional treatment methods mostly rely on surgery, and the emergence of selumetinib has brought a new molecular targeted treatment direction to patients.

In terms of usage and dosage, the dose of selumetinib is not fixed, but is adjusted individually based on the patient's body surface area (BSA). The general recommended dose is 25 mg/m², taken orally twice daily, approximately every 12 hours. Patients should take the medicine on an empty stomach, that is, avoid eating within 2 hours before each dose or 1 hour after taking the medicine, to ensure the best absorption of the medicine. Especially for pediatric patients, dosage allocation standards must be strictly followed to reduce adverse reactions and maintain stable efficacy.

The specific dosage range is as follows: There is currently no exact dosage recommendation for children with a body surface area less than 0.55m²; patients with a body surface area of 0.55-0.69m² take 20 mg orally in the morning and 10 mg in the evening; patients with a body surface area of 0.7-0.89m² take 20 mg each time twice a day; patients with a body surface area of 0.9-1.09m² take 20 mg each time twice a day. 5mg; patients with a body surface area of 1.1-1.29m², 30mg each time twice a day; patients with a body surface area of 1.3-1.49m², 35mg each time twice a day; patients with a body surface area of 1.5-1.69m², 40mg each time twice a day; patients with a body surface area of 1.7-1.89m², 45mg each time twice a day; patients with a body surface area of 1.9m² and above, 50mg each time twice a day. This dosage recommendation comes from the international clinical application experience of the original drug, which reflects the scientific nature and safety of selumetinib in precise dosing in children.

In terms of medication management, selumetinib capsules must be swallowed whole and should not be crushed, chewed or broken for use, as this may affect drug release characteristics and bioavailability. If you miss a dose, it is usually recommended not to take it again, but to continue taking the next dose as originally planned to prevent the accumulation of drugs in the body and cause toxic reactions.

Reference materials:https://www.koselugo.com